Xavier Marfà

Learn More
PURPOSE To define the maximum-tolerated dose of oxaliplatin given with cisplatin, protacted 96-h infusion of fluorouracil, and radiotherapy for patients with advanced esophageal cancer. PATIENTS AND METHODS Seventeen patients with locally advanced esophageal cancer and 2 patients with local recurrence were treated. Escalating doses of oxaliplatin,(More)
4544 Background: Although cisplatin is considered the cornerstone for the treatment of advanced bladder cancer, up to 50% of the patients (pts) cannot receive it because they are considered unfit mainly due to poor renal function. New non nephrotoxic regimens are needed. Gemcitabine and oxaliplatin are active, non-nephrotoxic and with non-overlapping(More)
This study was designed to evaluate the safety and tolerability of oxaliplatin combined with weekly boluses of 5-fluorouracil (5-FU) and low doses of leucovorin (LV) and to determine objective response, progression-free survival, and overall survival of patients with previously untreated advanced colorectal cancer. Seventy-nine patients enrolled in an(More)
Oxaliplatin (L-OHP), irinotecan (CPT-11) and 5-fluorouracil (5-FU) have shown their efficacy in metastatic colorectal cancer. The synergism of these drugs has been demonstrated in vivo and in vitro. The aim of this study was to determine the recommended dose of the triple combination of L-OHP, CPT-11 and CI 5-FU for a further phase II study. Eighteen(More)
4243 Background: Concurrent chemoradiotherapy with P and FU is superior to RT alone for locally advanced ES and GEJ carcinoma (Herskovic NEJM 1992) but at the cost of substantial toxicity. OXL has demonstrated activity in gastrointestinal tumors and overcome mismatch repair cisplatin-resistance in vitro. This study was undertaken to assess toxicity in(More)
  • 1